- Home
- HALO vs ARWR Comparison
HALO vs ARWR Comparison
Compare HALO & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HALO | ARWR |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.1B |
| IPO Year | 2001 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HALO | ARWR |
|---|---|---|
| Price | $69.40 | $63.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $78.18 | ★ $81.50 |
| AVG Volume (30 Days) | 2.0M | ★ 2.6M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 2.56 | 0.22 |
| Revenue | ★ $151,862,000.00 | $16,142,321.00 |
| Revenue This Year | $28.38 | N/A |
| Revenue Next Year | $12.72 | N/A |
| P/E Ratio | ★ $27.12 | $291.59 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.50 | $10.66 |
| 52 Week High | $82.22 | $76.76 |
Technical Indicators
Market Signals| Indicator | HALO | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 48.25 |
| Support Level | $67.94 | $60.53 |
| Resistance Level | $74.92 | $65.59 |
| Average True Range (ATR) | 2.53 | 2.71 |
| MACD | -0.82 | 0.07 |
| Stochastic Oscillator | 11.27 | 46.53 |
Price Performance
Historical ComparisonAbout HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.